drugset / Trial / NCT02707484

Summary

Gastrointestinal vascular malformation (GIVM), which is an important cause of acute or chronic gastrointestinal bleeding, currently lacks of effective treatment. The investigators' previous study first confirmed thalidomide treatment of GIVM bleeding was safe and effective. This prospective multi-center randomized controlled clinical trial intends to investigate the efficacy of thalidomide to the recurrent small intestinal hemorrhage due to GIVM.

Timeline

Start
2016-04
Primary completion
2020-12
Completion
2021-04

Outcome

Met primary endpoint

paper effective response in the 100-mg thalidomide group, 50-mg thalidomide group, and placebo group were 68.6%, 51.0%, and 16.0%, respectively (P<0.001 PMID 37913505 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral
Subject Thalidomide Other / unclassified 100 mg Oral

Indications